SCHEMBL2360872

SCHEMBL2360872

C(=Cc1ccccc1)CC1CCNCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.51
GBA1 P04062 1/20 0.50
CHRM1 P11229 1/20 0.50
CHRM3 P20309 1/20 0.50
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
SLC18A3 Q16572 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
HTR3A P46098 1/20 0.41
KCNH2 Q12809 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
GSTP1 P09211 1/20 0.39
IDO1 P14902 1/20 0.39
PAM P19021 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27593242 0.87 ALDH1A1 (0.49) ALDH1A1MAPTPOLBHPGDSIGMAR1
SCHEMBL18828589 0.87 ALDH1A1 (0.49) ALDH1A1MAPTPOLBHPGDSIGMAR1
SCHEMBL28139492 0.83 KDM4E (0.51) ALDH1A1MAPTPOLBHPGDSIGMAR1
SCHEMBL27666330 0.83 CHRM1 (0.51) KDM1AGBA1CHRM1CHRM3SLC6A2
SCHEMBL4321271 0.83 CHRM1 (0.42) KDM1AGBA1CHRM1CHRM3SIGMAR1
SCHEMBL4321273 0.83 CHRM1 (0.42) KDM1AGBA1CHRM1CHRM3SIGMAR1
SCHEMBL10784403 0.81 KDM4E (0.54) ALDH1A1MAPTPOLBHPGDSIGMAR1
SCHEMBL12735882 0.79 SIGMAR1 (0.63) KDM1AGBA1SIGMAR1SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL31556504 0.78 HTR2C (0.50) CHRM1CHRM3SIGMAR1SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL31556488 0.78 HTR2C (0.50) CHRM1CHRM3SIGMAR1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117567685-B High-wear-resistance solution polymerized styrene-butadiene rubber and preparation method thereof 新疆独山子石油化工有限公司 2024-04-16 CN disclosed
CN-117567685-A High-wear-resistance solution polymerized styrene-butadiene rubber and preparation method thereof 新疆独山子石油化工有限公司 2024-02-20 CN disclosed
US-20110263862-A1 PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS M'S SCIENCE CORPORATION (JP) 2011-10-27 US disclosed
EP-2357171-A1 PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS M's Science Corporation (JP) 2011-08-17 EP disclosed
US-20040044007-A1 Indoline derivatives H. LUNDBECK A/S (DK) 2004-03-04 US disclosed
EP-1345921-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. Lundbeck A/S (DK) 2003-09-24 EP disclosed
WO-2002051833-A1 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS H. LUNDBECK A/S (DK) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044007-A1 Indoline derivatives CNR1, GRIN2C, HTR3C KDM1A 902/4885GBA1 196/4885CHRM1 89/4885
US-20110263862-A1 PIPERIDINE DERIVATIVE, PIPERAZINE DERIVATIVE AND AGENT FOR TREATMENT OF DISEASE INVOLVING CENTRAL NERVOUS SYSTEM DISORDERS SIGMAR1, OPRL1, OPRK1 KDM1A 2961/4885GBA1 300/4885CHRM1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.